Mycobacteria: Leprosy and Non-Tuberculous Mycobacteria - Study Notes

Leprosy (Hansen's disease)

  • Causative agent and family: Mycobacterium leprae, part of the mycobacteria family; this group includes slow-growing mycobacteria that cause Hansen's disease.
  • Growth characteristics: M. leprae is slow-growing; this differentiates it from other mycobacteria. Note that non-mycobacterial TB is also slow-growing, but TB leans toward being slower than most non-tuberculous mycobacteria (this contrast was discussed to highlight growth rates among mycobacterial infections).
  • Disease spectrum and pathogenesis:
    • Causes Hansen's disease with prominent skin and peripheral nerve changes.
    • Immune-driven spectrum: tuberculoid-type reactions to lepromatous leprosy; tuberculoid is less disfiguring; lepromatous leprosy is the more disfiguring, superficial skin reaction, and is less common.
    • Spectrum reflects host immunity; more disfiguring lesions occur with weaker cell-mediated immunity (lepromatous form).
  • Epidemiology and reservoirs:
    • Incubation period ranges from 2\text{ to }10^+\text{ years} (i.e., between two years and more than ten years).
    • In the US, the nine-banded armadillo is the best-known reservoir; armadillos can harbor and transmit Mycobacterium leprae.
    • Outbreak monitoring:Recent observations (Florida) show ongoing presence in armadillos and local transmission risk; climate-related range shifts noted (e.g., armadillos reported in Kentucky). An example from a recent outbreak (Florida, armadillo found) illustrates that leprosy remains relevant.
  • Clinical features and diagnosis:
    • Primary manifestations are skin lesions and peripheral nerve involvement; may present with hypopigmented or anesthetic patches depending on the form.
    • Tuberculoid-type presentation: hypopigmented macula with sensory loss; may be mistaken for common pediatric infections like ringworm; key differentiator is sensory loss and nerve involvement rather than ring-like skin edge alone.
    • Lepromatous-type presentation: truly disfiguring skin lesions with superficial involvement; less common than TB.
    • Diagnosis requires a high index of suspicion; proceed to skin biopsy when suspected.
    • Biopsy and testing: skin biopsy with acid-fast bacilli (AFB) staining is typically used; sputum testing is not the primary route for leprosy since the organism resides in skin and nerves.
    • Differential diagnosis considerations: ringworm can look similar on exam, but loss of sensation and nerve involvement argue for leprosy.
  • Imaging and diagnosis context:
    • No universal microscopy criterion beyond AFB from skin; clinical suspicion plus biopsy confirms diagnosis; no standard sputum culture utility.
  • Treatment and prognosis:
    • Treatment relies on a multidrug regimen (details not specified in the lecture; focus on the fact that MDT is standard).
    • Prognosis varies; earlier recognition and treatment improve outcomes; leprosy remains underdiagnosed in some regions.
  • Practical and ethical considerations:
    • The disease is historically ancient and still present in certain areas; clinicians must balance differential diagnosis, duration of therapy, and potential adverse effects.
    • The patient’s quality of life and stigma considerations are relevant given skin changes and nerve involvement.
  • Miscellaneous notes referenced in the talk:
    • A heat map was shown to illustrate distribution (tuberculoid-type changes) around various regions; not necessary to memorize exact locations but useful for geographical awareness.
    • Climate-change-related shifts in reservoir and incidence were discussed to emphasize evolving epidemiology.

Non-Tuberculous Mycobacteria (NTM)

  • Overview and environment:
    • NTM comprises many species other than M. tuberculosis complex; there are well over 200 species found in the environment (soil, dust, and drinking water).
    • Transmission is environmental rather than primarily human-to-human; inhalation of aerosolized NTM from water sources is common; direct skin infection can occur.
  • Most clinically relevant NTM species:
    • MAC: Mycobacterium avium complex, the most clinically important group in practice; includes M. avium, M. intracellulare (sometimes referred to as M. avium-intracellulare), and M. chimaera. In clinical shorthand, “MAC” is often used when clinicians refer to nontuberculous mycobacterial disease.
    • Other rapidly growing NTMs: Abscessus (M. abscessus), Fortuitum (M. fortuitum), etc. These rapidly growing NTMs are named for their quicker growth in culture and can cause distinct clinical syndromes.
  • Major clinical syndrome:
    • Primarily pulmonary disease is emphasized for NTMs; other manifestations (cutaneous, disseminated) occur but are less central in this context.
  • Risk factors and populations at risk:
    • Structural lung disease: the highest risk includes bronchiectasis and COPD; pneumoconioses (silicosis, coal worker’s pneumoconiosis) also predispose due to impaired clearance.
    • Immunocompromised states.
    • Lady Windermere syndrome: classically an older, thinner female with low body mass index and often associated with mitral valve prolapse; this subset is a well-known clinical vignette on exams.
  • Clinical presentation:
    • Symptoms are nonspecific and resemble other chronic respiratory diseases: persistent cough, shortness of breath, weight loss, fatigue, low-grade fevers.
    • Symptoms overlap with COPD and bronchiectasis; exam findings vary with the underlying lung condition and may be non-specific.
  • Diagnosis: the triad is required for active NTM disease
    • Clinical: symptoms consistent with pulmonary disease or systemic involvement.
    • Imaging: cavities, bronchiectasis, or nodular infiltrates on chest imaging.
    • Microbiology: microbiologic evidence via sputum cultures (positive for NTM). Importantly, a positive culture alone is not sufficient for diagnosis.
    • Practical diagnostic challenge: NTM is ubiquitous in the environment, and colonization is common; therefore, many patients with a positive culture will not meet the full diagnostic triad.
    • A common teaching point: only about 14\% - 43\% of patients with a sputum culture positive for NTM will meet the full diagnostic criteria (clinical, imaging, and microbiologic criteria). Hence, diagnosis requires all three components.
  • Treatment considerations and prognosis:
    • Therapy is lengthy: typically 2-3\text{ years} with multi-drug regimens; this prolonged course increases the risk of adverse effects and non-adherence.
    • Discontinuation rates: around 14\% discontinue therapy due to intolerance or side effects; even after switching to second-line medications, adherence can be challenging.
    • Outcome considerations: because environmental exposure persists, a significant portion of patients (up to about 50\%) may experience reinfection or relapse after treatment.
    • Decision to treat vs. observation: treatment decisions depend on risk-benefit analysis, including patient age, comorbidities, symptom severity, likelihood of progression, and potential side effects; in some patients with slow-growing disease and limited life expectancy, clinicians may opt for conservative management rather than aggressive therapy.
  • HIV and MAC:
    • In people with HIV, MAC can be AIDS-defining when disseminated (extrapulmonary MAC is more common in severely immunocompromised patients).
    • With modern antiretroviral therapy, disseminated MAC has become far less common than in the ART-era prior to widespread ART access.
    • Prophylaxis in HIV: for patients with CD4 counts <40-50 cells/µL not on ART, prophylaxis is recommended (commonly with azithromycin or clarithromycin; alternatives include rifabutin in certain regimens).
  • Practical and ethical considerations:
    • Given the lengthy treatment and potential toxicity, clinicians weigh symptom relief against long-term survival benefit; some patients experience symptom improvement without clear evidence of extended life expectancy.
    • The environmental ubiquity and potential for reinfection require ongoing monitoring and, in some cases, a discussion about lifestyle and environmental exposures.
  • Application and clinical pearls:
    • When confronted with a patient who has COPD, bronchiectasis, or prior lung disease, NTM infection should be considered in the differential for chronic cough and radiographic cavities or nodular infiltrates.
    • The diagnostic triad is essential: do not treat solely on a positive sputum culture; correlate with clinical symptoms and imaging findings.
    • In HIV, be mindful of MAC as a potential opportunistic infection; prophylaxis guidelines hinge on CD4 counts and ART status.